ArticleBMC oral health2026
Salivary cortisol as a neuroendocrine stress biomarker for xerostomia in multiple sclerosis patients: a comparative cross-sectional study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundXerostomia is a common and clinically relevant complaint in patients with multiple sclerosis (MS), adversely affecting oral health, nutrition, and the quality of life. Neuroendocrine and autonomic dysregulation associated with MS may contribute to salivary gland dysfunction. It was hypothesized that MS patients with xerostomia would indicate higher salivary cortisol levels compared to individuals without xerostomia, the independent of self-reported anxiety.
methodsIn this comparative cross-sectional study, 39 MS patients were enrolled, including 23 with xerostomia and 16 without. Demographic characteristics, medication use, salivary cortisol concentrations, xerostomia severity, and anxiety levels were assessed. Unstimulated whole saliva was collected using the spitting method, and cortisol levels were quantified by enzyme-linked immunosorbent assay (ELISA). Furthermore, xerostomia was evaluated clinically using the Abslang test and subjectively using the Short Xerostomia Inventory (SXI). Anxiety was also assessed using the Beck Anxiety Inventory (BAI).
resultsNo significant differences were observed between the groups in terms of age, gender, medication use, or other assessed confounding factors. The patients with xerostomia demonstrated significantly higher salivary cortisol levels than controls (8.5 ± 1.8 vs. 4.7 ± 2.2 ng/mL, p = 0.045) and greater xerostomia severity scores (7.10 ± 2.20 vs. 2.80 ± 1.50, p = 0.001). In contrast, the anxiety scores were significantly lower in the xerostomia group compared with the controls (11.77 ± 8.30 vs. 17.23 ± 10.21, p = 0.03).
conclusionsSalivary cortisol levels were associated with the presence and severity of xerostomia in MS patients, despite lower self-reported anxiety levels. This lack of association demonstrates that salivary cortisol may reflect physiological stress or neuroendocrine/autonomic dysregulation rather than subjective anxiety alone. While causality cannot be inferred due to the cross-sectional design, these findings support the potential role of salivary cortisol as a biomarker for xerostomia in MS and provide the importance of integrating biological stress markers into oral health assessment in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.